FeLV detection in feline samples: scope and limits of a diagnostic evaluation

Virology journal · 2025

In plain language

The study assessed FeLV detection in cat samples in the laboratory, not in a known number of individual cats. The final comparison included 50 samples after four initially positive samples were excluded because their PCR results were negative. The results do not guarantee that the test will be free of errors in other cats. The study did not assess lymphoma or leukemia as cancers and does not establish how the test performs in cats with those cancers or with latent or regressive infection.

Scientific detail

The study published in Virology journal in 2025 (doi: 10.1186/s12985-025-03015-y) evaluated FeLV antigen detection in vitro in feline specimens. The initial collection comprised 54 samples: 36 initially FeLV-positive and 18 initially FeLV-negative. The number of individual cats was not reported, and their age, living environment, and medical history were unavailable. This missing information prevents characterization of any lymphoma or leukemia subgroup.

Four initially FeLV-positive samples were excluded because they tested negative for proviral DNA by PCR. The final comparison included 50 samples: 32 PCR-positive and 18 PCR-negative. Early or atypical infection as a possible explanation for this discordance is speculative and was not experimentally established. The resulting comparison does not establish test performance in this discordant subgroup. The empirical claims provided are rated evidence level C, reflecting a limited, unreplicated diagnostic evaluation.

The authors acknowledge that the sample may not capture field variability and that false-positive and false-negative results remain possible in broader applications. Error rates outside the tested sample set are not quantified. Each assay was represented by a single lot; batch variability or sample characteristics could influence the comparative results. Additional appraisal limitations include exclusion of initially positive/PCR-negative samples, the absence of reported confidence intervals, and the lack of performance results stratified by sample matrix or infection stage.

From an oncology perspective, the study concerns ascertainment of FeLV status rather than oncogenesis. It did not measure lymphoma or leukemia incidence, tumor-associated provirus, insertional oncogenesis, cancer prognosis, or other oncological outcomes. The diagnostic agreement reported in these selected samples does not establish sensitivity for FeLV-associated lymphoma or leukemia, or performance in cats with FeLV-associated malignancy or latent or regressive infection. Nor does it demonstrate a mechanism of oncogenesis; this scope assessment does not imply that FeLV lacks an oncogenic role.

What we know

FeLV antigen detection was evaluated in vitro in feline samples. Of the 54 initial samples, four initially positive samples were excluded after testing negative for proviral DNA by PCR; the final comparison comprised 32 PCR-positive and 18 PCR-negative samples. The empirical evidence is level C and comes from a limited, unreplicated evaluation. The authors acknowledge that false-positive and false-negative results may occur in broader applications.

What we don't know

The number of individual cats contributing samples was not reported, and their age, living environment, and medical history were unavailable. Error rates outside the tested sample set, performance in the excluded discordant samples, and performance by sample matrix or infection stage were not established. Performance in cats with FeLV-associated malignancy or latent or regressive infection was not established either. Oncological outcomes and mechanisms of oncogenesis were not evaluated.

Evidence

Provenance

This project does not diagnose or prescribe. Always consult your veterinarian.